Editas Medicine Inc
Fermé
SecteurSoins de santé
2.48 1.64
Résumé
Variation du prix de l'action
24h
Min
2.48
Max
2.51
Revenu | -19M -25M |
|---|---|
Ventes | -22M 2.8M |
BPA | -0.26 |
Marge bénéficiaire | -882.444 |
Employés | 87 |
EBITDA | -19M -25M |
Recommandations | Achat |
|---|---|
Prévisions sur 12 Mois | +188% upside |
Prochains Résultats | 10 août 2026 |
|---|
Capitalisation Boursière | 112M 406M |
|---|---|
Ouverture précédente | 0.84 |
Clôture précédente | 2.48 |
Sentiment de l'Actualité
By Acuity
50%
50%
146 / 342 Classement par Healthcare
Editas Medicine Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.